Odyssey Therapeutics, Inc. (ODTX) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$54.43M*; Operating income -$55.47M; Depreciation and amortization $1.04M*.
- 2026-03-31: Basis Reported; EBITDA -$38.61M; Operating income (m); Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA -$40.65M*; Operating income -$41.92M; Depreciation and amortization $1.27M*.
- 2025-03-31: Basis Reported; EBITDA -$37.86M; Operating income (m); Depreciation and amortization (m).
Complete source-backed ebitda history.
- Available history
- 2025-03-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$54.43M* | -$55.47M | $1.04M* | $0.00 | (m) | $186.00K* | -$34.51M* | (m) | $36.23M | (m) | -$8.00K |
|---|
| 2026-03-31 | Reported | -$38.61M | (m) | (m) | (m) | (m) | $148.00K | -$41.03M | (m) | $32.32M | (m) | $63.00K |
|---|
| 2025-06-30 | Reported | -$40.65M* | -$41.92M | $1.27M* | $959.00K | -4239.21%* | $29.00K* | -$34.26M* | (m) | $30.23M | (m) | $30.00K |
|---|
| 2025-03-31 | Reported | -$37.86M | (m) | (m) | (m) | -1973.98% | $927.00K | -$38.62M | (m) | $38.77M | (m) | $140.00K |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|